PE Biosystems Eyeing Spin-out Of Expanded Molecular Diagnostic Business
This article was originally published in The Gray Sheet
Executive Summary
PE Corp. is looking to leverage the capabilities of its two component business units, PE Biosystems and Celera Genomics, to increase the company's presence in the molecular diagnostics field, most likely through a spin-out of the new operation.
You may also be interested in...
Celera Diagnostics To Develop Genetic Tests For Hospitals And Labs
Celera Diagnostics will develop genetic tests aimed at the $1 bil. molecular diagnostic market, which is currently growing at a 30% clip, as part of a recently launched business strategy to commercialize products based on analysis of the human genome.
Celera Diagnostics To Develop Genetic Tests For Hospitals And Labs
Celera Diagnostics will develop genetic tests aimed at the $1 bil. molecular diagnostic market, which is currently growing at a 30% clip, as part of a recently launched business strategy to commercialize products based on analysis of the human genome.
Celera Proteomics Facility On-Line With Goal Of 1 Mil. Sequences Daily
Celera Genomics' newly constructed, 33,000 square foot proteomics facility in Rockville, Maryland will be able to sequence 1 mil. proteins daily in a search for new disease diagnostic markers once it is fully operational, the firm says.